Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market

Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.